<DOC>
	<DOCNO>NCT03052127</DOCNO>
	<brief_summary>The primary objective ass safety , immunogenicity preliminary efficacy single treatment one two dose level Light-activated AU-011 treatment subject primary choroidal melanoma .</brief_summary>
	<brief_title>Phase 1B Study Subjects With Small Medium Primary Choroidal Melanoma</brief_title>
	<detailed_description>This phase 1B open-label , single ascend dose clinical trial design evaluate safety two dose level Light-activated AU-011 treatment subject small medium primary choroidal melanoma . Throughout study , subject monitor medical ophthalmic assessment . Subjects follow total 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis uveal melanoma Have know contraindication sensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>Eye cancer</keyword>
	<keyword>Ocular melanoma</keyword>
	<keyword>Choroidal melanoma</keyword>
</DOC>